

IDERA PHARMACEUTICALS, INC.

Form SC 13G

December 15, 2006

**Table of Contents**

OMB APPROVAL  
OMB Number: 3235-0145  
Expires: December 31, 2005  
Estimated average burden  
hours per response.....11

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934  
(Amendment No. \_\_\_\_)\***

Idera Pharmaceuticals, Inc.  
(Name of Issuer)  
Common Stock, \$0.001 par value  
(Title of Class of Securities)  
45168K 30 6  
(CUSIP Number)  
December 8, 2006  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table of Contents**

CUSIP No. 45168K 30 6 13G Page 2 of 5

NAMES OF REPORTING PERSONS:

1

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

Merck & Co., Inc.  
22-1109110

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

2

- (a)
- (b)

SEC USE ONLY:

3

CITIZENSHIP OR PLACE OF ORGANIZATION:

4

New Jersey

SOLE VOTING POWER:

5

NUMBER OF 1,818,182

SHARED VOTING POWER:

SHARES BENEFICIALLY OWNED BY 6 0

SOLE DISPOSITIVE POWER:

EACH REPORTING PERSON 7 1,818,182

SHARED DISPOSITIVE POWER:

WITH: 8 0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

9

1,818,182

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

9.08%

**12** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

CO

---

**TABLE OF CONTENTS**

Item 1. (a) Name of Issuer:

Item 1. (b) Address of Issuer's Principal Executive Offices:

Item 2. (a) Name of Person Filing:

Item 2. (b) Address of Principal Business Office or, if None, Residence:

Item 2. (c) Citizenship

Item 2. (d) Title of Class of Securities

Item 2. (e) CUSIP Number

Item 3.

Item 4. Ownership

Item 5. Ownership of Five Percent or Less of a Class

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Item 8. Identification and Classification of Members of the Group

Item 9. Notice of Dissolution of Group

Item 10. Certification

SIGNATURE

---

**Table of Contents**

Page 3 of 5 Pages

**Item 1.(a) Name of Issuer:**

Idera Pharmaceuticals, Inc.

**Item 1.(b) Address of Issuer's Principal Executive Offices:**

345 Vassar Street

Cambridge, Massachusetts 02139

**Item 2. (a) Name of Person Filing:**

Merck & Co., Inc.

**Item 2. (b) Address of Principal Business Office or, if None, Residence:**

Merck & Co., Inc.

One Merck Drive

Whitehouse Station, New Jersey 08889-0100

**Item 2. (c) Citizenship**

New Jersey

**Item 2. (d) Title of Class of Securities**

Common Stock, par value \$0.001 per share.

**Item 2. (e) CUSIP Number.**

45168K 30 6

**Item 3.**

Not applicable as this Schedule is filed pursuant to Rule 13d-1(c).

---

**Table of Contents**

Page 4 of 5 Pages

**Item 4. Ownership.**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: 1,818,182

(b) Percent of class: 9.08%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote: 1,818,182

(ii) Shared power to vote or to direct the vote: \_\_\_\_\_

(iii) Sole power to dispose or to direct the disposition of: 1,818,182

(iv) Shared power to dispose or to direct the disposition of: \_\_\_\_\_

**Item 5. Ownership of Five Percent or Less of a Class**

Not Applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not Applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person**

Not Applicable.

**Item 8. Identification and Classification of Members of the Group**

Not Applicable.

**Item 9. Notice of Dissolution of Group**

Not Applicable.

---

**Table of Contents**

Page 5 of 5 Pages

**Item 10. Certification.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: December 15, 2006

Merck & Co., Inc.

By: /s/ Celia A. Colbert

Name: Celia A. Colbert

Title: Vice President, Secretary and  
Assistant General Counsel